Southeastern Research Center

Winston-Salem, North Carolina 27103-4029

8 studies enrolling now · 41 studies all time

What they study most

Asthma, Bronchiectasis, CDI, COPD, COPD (Chronic Obstructive Pulmonary Disease), Chronic Cough, Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease (COPD), Clostridioides Difficile, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, Clostridium Difficile

Studies at this site

• An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL) — Recruiting now
• A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis — Recruiting now
• A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) — Recruiting now
• Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension — Recruiting now
• A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease — Recruiting now
• A Study to Evaluate Solrikitug in Participants With COPD (ZION) — Recruiting now
• Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis — Recruiting now
• Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis — Stopped early
• Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease — Enrolling by invitation
• A Study to Test Whether Different Doses of BI 1291583 Help People With Bronchiectasis — Completed
• A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis — Completed
• A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. — Running, not enrolling
• A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis — Running, not enrolling
• LYT-100 in Post-acute COVID-19 Respiratory Disease — Stopped early
• A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease — Running, not enrolling
• Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis — Completed
• A Study to Evaluate Solriktug in Adult Participants With Asthma — Running, not enrolling
• A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease — Completed
• A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease — Stopped early
• A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis — Stopped early
• A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD — Running, not enrolling
• Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF — Completed
• LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) — Running, not enrolling
• Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules — Running, not enrolling
• Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough — Completed
• A Study to Investigate Leramistat in Patients With IPF — Withdrawn before enrolling
• A Study in People With Pulmonary Fibrosis to Monitor Cough With a Wearable Device — Completed
• Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis — Completed
• A Registry to Evaluate the Performance of the BDX-XL2 Test — Completed
• Evaluation of S-600918 in Adults With Refractory Chronic Cough — Completed
• Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection — Completed
• Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis — Completed
• A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) — Completed
• Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE] — Completed
• Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough — Completed
• A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale — Completed
• Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) — Completed
• The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus — Completed
• A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects — Stopped early
• A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD — Completed